Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 121,433 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Chronic Lymphocytic Leukemia, CLL
Interventions: Revlimid, Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Stroke, Ischemic Stroke
Interventions: "Hopkins" post tPA for ischemic stroke monitoring protocol; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Perifosine, Temsirolimus, Therapeutic Conventional Surgery; Other · Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: [F-18]PBR06, [C-11]Methylreboxetine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Interventions: daptomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Cypress, California • Minneapolis, Minnesota

Conditions: Pediatric Obesity, Risk Reduction Behavior, Early Intervention, Intergenerational Relations
Interventions: Caregiver Component., Caregiver-Preschooler Learning., Center-based Preschooler Component.; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Healthy
Interventions: KB5, SG1, Lactulose; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Corneal and Endothelial Cell Measurements
Interventions: Not listed
Lead sponsor: Nidek Co. LTD.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Cystic Fibrosis
Interventions: RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5; Device · Other
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more

Conditions: Parkinson's Disease
Interventions: Tai Chi, Strength training, Low-Impact Exercise Control; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 40 Years to 85 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide, Suicidal Ideation
Interventions: BE-SMART-DR, psychoeducational control comparator condition (CC); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 16 Years to 29 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Medication Non-adherence
Interventions: Mindfulness Training (MT); Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Postural Tachycardia Syndrome, Orthostatic Intolerance
Interventions: Carbidopa, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: PreDiabetes, Obesity, Childhood
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 22 Years
Enrollment: 772 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depression, Dysthymia, Depression NOS
Interventions: escitalopram + bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Torrance, California • Denver, Colorado • Miami, Florida + 4 more

Conditions: Atherosclerosis of Native Arteries of the Extremities
Interventions: ELUVIA (Stent Implantation), Zilver PTX (Stent Implantation); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 42
States / cities: Yuma, Arizona • Sacramento, California • Gainesville, Florida + 38 more

Conditions: Postmenopausal Osteoporosis, Osteoporosis
Interventions: synthetic hPTH 1-34; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 46 Years to 85 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma, Myeloma
Interventions: Busulfan, Fludarabine, Campath, Stem Cell Transplant; Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prematurity, Neurodevelopmental Disorder, Carnitine Deficiency
Interventions: L-carnitine, 5% Dextrose; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 1 Day to 3 Days
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Colorectal Cancer Metastatic
Interventions: FOLFOX6m, SIR-Spheres microspheres; Drug · Device
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more

Conditions: Melanoma
Interventions: Interferon alpha; Biological
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Overweight and Obesity
Interventions: Standard Care, Daily Self-Weighing; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Smoking
Interventions: THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA); Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Search by objective public record fields.

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

Study to Evaluate Daptomycin Given During Dialysis and After Dialysis

FirstStep2Health Intervention

A Clinical Study to Assess the Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects

Comparative Study of Specular Microscope for Cell Density, Coefficient of Variation, Hexagonality and Corneal Thickness

Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study

Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

Mind Your Heart Study

Peripheral Dopamine in Postural Tachycardia Syndrome

Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance

Are Two Antidepressants a Good Initial Treatment for Depression?

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Cognitive Effects of Interferon in Patients With Melanoma

Daily Self-Weighing for Obesity Management in Primary Care

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting